Materials used for the NR4A expression analyses and results of NR4A1 and NR4A3 expression compared with GCBs
| . | n . | Reduction of NR4A1 and NR4A3 . | Reduction of NR4A1 . | Fisher* . | ||||
|---|---|---|---|---|---|---|---|---|
| n (%) > 50% . | n (%): 50% to 25% . | n (%) < 25% . | n (%) > 50% . | n (%): 50% to 25% . | n (%) < 25% . | P . | ||
| Nonneoplastic controls | ||||||||
| Peripheral CD19+ B cells | 4 | — | — | 4 (100%) | — | — | 4 (100%) | na |
| Peripheral CD3+ T cells | 4 | — | — | 4 (100%) | — | — | 4 (100%) | na |
| Hyperplastic lymph nodes | 9 | — | 4 (44%) | 5 (56%) | — | 4 (44%) | 5 (56%) | ns |
| GCBs | 5 | — | — | 5 (100%) | — | — | 5 (100%) | na |
| Mantle cells | 5 | — | — | 5 (100%) | — | — | 5 (100%) | na |
| Marginal zone B cells | 5 | — | — | 5 (100%) | — | — | 5 (100%) | na |
| Tonsillar CD3+ T cells | 5 | — | 2 (40%) | 3 (60%) | — | 3 (60%) | 2 (40%) | ns |
| Indolent NHLs | ||||||||
| B-CLL | 7 | 5 (71%) | 2 (29%) | — | 6 (86%) | 1 (14%) | — | .001 |
| FLII | 10 | 7 (70%) | 2 (20%) | 1 (10%) | 7 (70%) | 2 (20%) | 1 (10%) | .002 |
| MZBCL | 15 | 9 (60%) | — | 6 (40%) | 9 (60%) | — | 6 (40%) | .038 |
| MALT lymphoma | 6 | 3 (50%) | — | 3 (50%) | 3 (50%) | — | 3 (50%) | ns |
| Nodal MZBCL | 9 | 6 (67%) | — | 3 (33%) | 6 (67%) | — | 3 (33%) | .031 |
| Hairy cell leukemia | 8 | 2 (25%) | 1 (12.5%) | 5 (62.5%) | 2 (25%) | 1 (12.5%) | 5 (62.5%) | ns |
| Morbus Waldenström | 7 | 2 (29%) | 2 (29%) | 3 (42%) | 4 (57%) | 3 (43%) | — | .001 |
| Immunocytoma | 15 | 5 (33%) | 1 (7%) | 9 (60%) | 7 (46%) | 4 (27%) | 4 (27%) | .016 |
| Multiple myeloma | 6 | — | — | 6 (100%) | — | — | 6 (100%) | na |
| B-cell prolymphocytic leukemia | 7 | 1 (14%) | — | 6 (86%) | 2 (28%) | — | 5 (72%) | .470 |
| Aggressive NHLs | ||||||||
| FLIII | 12 | 9 (75%) | 3 (25%) | — | 10 (83%) | 2 (17%) | — | <.001 |
| BL | 5 | 3 (60%) | 1 (20%) | 1 (20%) | 3 (60%) | 1 (20%) | 1 (20%) | .048 |
| PMBCL | 5 | 5 (100%) | — | — | 5 (100%) | — | — | .008 |
| DLBCL | 23 | 20 (87%) | 1 (4%) | 2 (9%) | 21 (91%) | — | 2 (9%) | <.001 |
| MCL | 9 | 7 (78%) | — | 2 (22%) | 8 (89%) | — | 1 (11%) | .003 |
| Peripheral T-cell NHL | 8 | — | — | 8 (100%) | — | 2 (25%) | 6 (75%) | ns |
| HD | 9 | 6 (67%) | 1 (11%) | 2 (22%) | 6 (67%) | 1 (11%) | 2 (22%) | .021 |
| ALL | 8 | 6 (75%) | 2 (25%) | — | 6 (75%) | 2 (25%) | — | .001 |
| . | n . | Reduction of NR4A1 and NR4A3 . | Reduction of NR4A1 . | Fisher* . | ||||
|---|---|---|---|---|---|---|---|---|
| n (%) > 50% . | n (%): 50% to 25% . | n (%) < 25% . | n (%) > 50% . | n (%): 50% to 25% . | n (%) < 25% . | P . | ||
| Nonneoplastic controls | ||||||||
| Peripheral CD19+ B cells | 4 | — | — | 4 (100%) | — | — | 4 (100%) | na |
| Peripheral CD3+ T cells | 4 | — | — | 4 (100%) | — | — | 4 (100%) | na |
| Hyperplastic lymph nodes | 9 | — | 4 (44%) | 5 (56%) | — | 4 (44%) | 5 (56%) | ns |
| GCBs | 5 | — | — | 5 (100%) | — | — | 5 (100%) | na |
| Mantle cells | 5 | — | — | 5 (100%) | — | — | 5 (100%) | na |
| Marginal zone B cells | 5 | — | — | 5 (100%) | — | — | 5 (100%) | na |
| Tonsillar CD3+ T cells | 5 | — | 2 (40%) | 3 (60%) | — | 3 (60%) | 2 (40%) | ns |
| Indolent NHLs | ||||||||
| B-CLL | 7 | 5 (71%) | 2 (29%) | — | 6 (86%) | 1 (14%) | — | .001 |
| FLII | 10 | 7 (70%) | 2 (20%) | 1 (10%) | 7 (70%) | 2 (20%) | 1 (10%) | .002 |
| MZBCL | 15 | 9 (60%) | — | 6 (40%) | 9 (60%) | — | 6 (40%) | .038 |
| MALT lymphoma | 6 | 3 (50%) | — | 3 (50%) | 3 (50%) | — | 3 (50%) | ns |
| Nodal MZBCL | 9 | 6 (67%) | — | 3 (33%) | 6 (67%) | — | 3 (33%) | .031 |
| Hairy cell leukemia | 8 | 2 (25%) | 1 (12.5%) | 5 (62.5%) | 2 (25%) | 1 (12.5%) | 5 (62.5%) | ns |
| Morbus Waldenström | 7 | 2 (29%) | 2 (29%) | 3 (42%) | 4 (57%) | 3 (43%) | — | .001 |
| Immunocytoma | 15 | 5 (33%) | 1 (7%) | 9 (60%) | 7 (46%) | 4 (27%) | 4 (27%) | .016 |
| Multiple myeloma | 6 | — | — | 6 (100%) | — | — | 6 (100%) | na |
| B-cell prolymphocytic leukemia | 7 | 1 (14%) | — | 6 (86%) | 2 (28%) | — | 5 (72%) | .470 |
| Aggressive NHLs | ||||||||
| FLIII | 12 | 9 (75%) | 3 (25%) | — | 10 (83%) | 2 (17%) | — | <.001 |
| BL | 5 | 3 (60%) | 1 (20%) | 1 (20%) | 3 (60%) | 1 (20%) | 1 (20%) | .048 |
| PMBCL | 5 | 5 (100%) | — | — | 5 (100%) | — | — | .008 |
| DLBCL | 23 | 20 (87%) | 1 (4%) | 2 (9%) | 21 (91%) | — | 2 (9%) | <.001 |
| MCL | 9 | 7 (78%) | — | 2 (22%) | 8 (89%) | — | 1 (11%) | .003 |
| Peripheral T-cell NHL | 8 | — | — | 8 (100%) | — | 2 (25%) | 6 (75%) | ns |
| HD | 9 | 6 (67%) | 1 (11%) | 2 (22%) | 6 (67%) | 1 (11%) | 2 (22%) | .021 |
| ALL | 8 | 6 (75%) | 2 (25%) | — | 6 (75%) | 2 (25%) | — | .001 |
MALT, mucosa associated lymphoid tissue; na, not applicable because of equality; ns, not significant.
Fisher’s exact test was used to compare the NR4A1 expression distribution to GCBs.